US-REGISTERED COMPANY
Tesamorelin is a modified analog of growth hormone-releasing hormone (GHRH). Its structural modification was developed to change stability relative to the natural GHRH sequence while retaining interest in the GHRH receptor and GH/IGF-1 axis.
Why modify peptide analogs?
Natural peptides can be rapidly degraded by proteases. An amino-acid or chemical modification can affect enzymatic stability, receptor binding and signal duration in an experimental system. Results from one analog should not automatically be transferred to another.
Laboratory endpoints
- GHRH receptor activation
- cAMP and downstream responses
- proteolytic stability
- GH and IGF-1 biomarkers in suitable models
- comparison of modified and unmodified sequences
Tesamorelin and sermorelin
Both relate to the GHRH axis, but they are not the same molecule. Sermorelin corresponds to the shorter GHRH(1-29) concept, while tesamorelin has its own structural modification and distinct research context.
Related laboratory material
See the neutrally labeled TH Peptide 10 mg and Sermorelin vs Tesamorelin.
Further reading
PubMed: tesamorelin and GHRH signaling
RESEARCH USE ONLY: This educational content concerns laboratory and scientific research. Peptiva research materials are not medicines and are not intended for use in humans or animals.